文献速递细胞病理与分子病理

甲状腺RAS突变与恶性风险:FNA细胞学-组织学对照研究

RAS mutation and associated risk of malignancy in the thyroid gland: An FNA study with cytology-histology correlation.
PubMed 文献 · Cancer Cytopathol · 2021-11-30

本研究回顾性分析了2015年1月至2021年5月间127例甲状腺FNA中检出RAS突变的病例,其中72例有组织学随访。总体RAS突变相关恶性风险(ROM)为29%,仅RAS突变时为18%;孤立NRAS、HRAS、KRAS突变相关ROM分别为15%、27%、14%。Bethesda IV类病例ROM高于III类(38% vs 17%)。

要点

  • 总体RAS突变相关ROM为29%,仅RAS突变时为18%。
  • 孤立HRAS突变ROM(27%)高于NRAS(15%)和KRAS(14%)。
  • Bethesda IV类病例ROM高于III类(38% vs 17%)。

核心结论

  • 甲状腺FNA中RAS突变相关总体ROM为中等(29%)。
  • 孤立HRAS突变ROM(27%)高于NRAS(15%)和KRAS(14%)。

研究设计与样本

  • 回顾性研究,检索2015年1月至2021年5月电子数据库。
  • 共纳入127例RAS突变甲状腺FNA病例,年龄51±14岁,女100例、男27例。
  • 72例有组织学随访。
  • 分子检测采用ThyroSeq Genomic Classifier、ThyGeNEXT/ThyraMIR或ThyroSure基因panel。

主要发现

  • 总体RAS突变(伴或不伴其他分子改变)相关ROM为29%。
  • 仅RAS突变时ROM为18%。
  • 孤立NRAS、HRAS、KRAS突变相关ROM分别为15%、27%、14%。
  • Bethesda IV类病例ROM高于III类(38% vs 17%)。
  • 21例组织学确诊恶性病例中,细胞学分类为IV类14/34(41%)、III类6/35(17%)、V类1/1(100%)。

临床怎么用

  • 甲状腺FNA检出RAS突变时,应结合细胞学Bethesda分类评估恶性风险。
  • 孤立HRAS突变可能提示较高ROM,需更积极随访或诊断。

局限性

  • 仅72例有组织学随访,部分病例缺乏组织学确认。
  • 回顾性单中心研究,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Activating point mutations of the RAS gene (NRAS, HRAS, and KRAS) can be seen in benign and malignant thyroid tumors; among these, NRAS mutations are more commonly seen. This study was conducted to evaluate the thyroid risk of malignancy (ROM) associated with RAS mutations in thyroid fine-needle aspiration (FNA) at the authors' institution. METHODS: The authors searched their electronic database system between January 2015 and May 2021 for thyroid FNA cases with any type of RAS mutation. Molecular alterations were identified with the ThyroSeq Genomic Classifier, ThyGeNEXT (thyroid oncogene panel)/ThyraMIR (miRNA classifier), or ThyroSure gene panel. RESULTS: A total of 127 cases (age, 51 ± 14 years; 100 females and 27 males) were identified, and 72 had histologic follow-up. The overall ROM associated with RAS mutations (with or without any other molecular alterations) was 29%, whereas the ROM was lower (18%) with RAS mutations only. Isolated NRAS, HRAS, and KRAS mutation-associated ROMs were 15%, 27%, and 14%, respectively. Among these RAS-mutated cases, the cases with a Bethesda category IV cytologic diagnosis had a higher ROM than the cases with a category III diagnosis (38% vs 17%). Twenty-one histologically confirmed malignant cases were mostly classified on cytology as category IV lesions (14 of 34; 41%), and the remainder were either category III (6 of 35; 17%) or V lesions (1 of 1; 100%). CONCLUSIONS: This study demonstrated that the overall RAS mutation-associated ROM in thyroid FNA was intermediate (29%), and isolated HRAS mutations appeared to have a higher ROM (27%) than NRAS and KRAS mutations (15% and 14%, respectively).

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Gilani SM, Abi-Raad R, Garritano J, et al. RAS mutation and associated risk of malignancy in the thyroid gland: An FNA study with cytology-histology correlation. Cancer Cytopathol. 2021. PMID: 34847284. doi:10.1002/cncy.22537

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。